Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "clinical-trial"

768 News Found

USFDA approves Edwards Mitris Resilia valve
Medical Device | March 31, 2022

USFDA approves Edwards Mitris Resilia valve

The valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve


OPPI summit calls for collaboration across stakeholders
News | March 30, 2022

OPPI summit calls for collaboration across stakeholders

The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India


Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors
Drug Approval | March 30, 2022

Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors

Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding


Philips expands network of clinical partners for early diagnosis and treatment of lung cancer
Medical Device | March 28, 2022

Philips expands network of clinical partners for early diagnosis and treatment of lung cancer

Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases


Vela Diagnostics launches NGS-based pan-cancer panels
Medical Device | March 28, 2022

Vela Diagnostics launches NGS-based pan-cancer panels

Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options


Aquavit Files IND with USFDA for DTX-021, a new botulinum toxin
Drug Approval | March 25, 2022

Aquavit Files IND with USFDA for DTX-021, a new botulinum toxin

Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA


Pfizer granted USFDA Breakthrough Therapy Designation for RSV vaccine candidate
Drug Approval | March 24, 2022

Pfizer granted USFDA Breakthrough Therapy Designation for RSV vaccine candidate

The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age


Totus Medicines partners with Mila on a mission to treat the untreatable
Biotech | March 24, 2022

Totus Medicines partners with Mila on a mission to treat the untreatable

Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale


Huma acquires AstraZeneca health platform AMAZE
Digitisation | March 23, 2022

Huma acquires AstraZeneca health platform AMAZE

As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials


Bristol Myers Squibb to demonstrate growing cardiovascular portfolio
Biotech | March 22, 2022

Bristol Myers Squibb to demonstrate growing cardiovascular portfolio

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease